The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2017

Filed:

Jul. 23, 2012
Applicants:

Ilijas Jelcic, Zurich, CH;

Roland Martin, Zurich, CH;

Sven Schippling, Zurich, CH;

Mireia Sospedra, Zurich, CH;

Sara Yousef, Hamburg, DE;

Inventors:

Ilijas Jelcic, Zurich, CH;

Roland Martin, Zurich, CH;

Sven Schippling, Zurich, CH;

Mireia Sospedra, Zurich, CH;

Sara Yousef, Hamburg, DE;

Assignee:

UNIVERSITAET ZUERICH, Zurich, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/70 (2006.01); C07K 14/005 (2006.01); A61K 39/12 (2006.01); A61K 38/20 (2006.01); C07K 7/08 (2006.01); A61K 38/16 (2006.01); A61K 38/00 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/005 (2013.01); A61K 38/2046 (2013.01); A61K 39/12 (2013.01); C07K 7/08 (2013.01); C12Q 1/70 (2013.01); A61K 38/00 (2013.01); A61K 38/162 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55527 (2013.01); C12N 7/00 (2013.01); C12N 2710/22022 (2013.01); C12N 2710/22023 (2013.01); C12N 2710/22034 (2013.01); C12N 2710/22071 (2013.01);
Abstract

The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML) and/or progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS). Individuals in danger of such PML or PML-IRIS may, e.g., be immuno-compromised or immunosuppressed patients or patients having an autoimmune disease eligible for immunosuppressive treatment. The invention also relates to compositions comprising at least one CD4+ epitope of a JCV protein and to therapeutic, prophylactic and diagnostic uses thereof.


Find Patent Forward Citations

Loading…